Medirom Healthcare Technologies Inc.

MRM

MEDIROM Healthcare Technologies Inc., together with its subsidiaries, provides holistic health services in Japan. It operates in three segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty. The Relaxation Salon segment develops, owns, operates, franchises, and supports relaxation salons, which provide finger-pressure style bodywork therapy, stretch therapy, and posture and joint alignment, as well as physical therapy elements; and various individual services, including anti-fatigue therapy, athletic support therapy, slim-down therapy, and reflexology.

About the company

Country: JapanPrice: $0.28Market Cap: $2.2M

Investment snapshot

12%positive consensus

Scored 1d ago

Positive

BUY / PASS

Neutral / negative

4 / 10

NEUTRAL / FAIL

Median fair value

$3.11

+1022.7% vs price

Models with upside

6 / 17

Positive margin of safety

Strongest signal

MRM undervalued: all 6 models price fair value above $0.28 (median $3.11)

Key risk

11 of 12 flag MRM's debt & leverage — Graham, Buffett, Lynch +8 more

Framework analysis

Verdict	Meaning
BUY	Positive purchase signal: the framework's buy requirements are met.
PASS	The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRAL	Neither a positive nor negative conclusion. It does not mean to hold an existing position.
FAIL	The company does not clear the framework's requirements.
Ranked	Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

Metric	Graham Defensive Value	Buffett Quality Compounder	Lynch GARP	Greenblatt Magic Formula	Piotroski F-Score	Dreman Contrarian Value	Munger Quality Focus	Pabrai Dhandho Framework	Akre Three-Legged Stool	Marks Risk-Aware Value	Ackman Activist Value	Templeton Global Bargain Hunter	Sleep Scale Economies Shared	Asness Systematic Factors	Neff Low-P/E Total Return	Schloss Asset-Value Discipline	O'Shaughnessy Systematic Factor Composite
Verdict	FAIL	FAIL	FAIL	Not ranked	NEUTRAL	PASS	PASS	NEUTRAL	FAIL	FAIL	FAIL	NEUTRAL	FAIL	FAIL	FAIL	FAIL	NEUTRAL
Score
Analysis	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…
Intrinsic Value (annual)				N/A	N/A		N/A			N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Margin of Safety	+84.2%	+92.1%	+93.9%	N/A	N/A	+89.8%	N/A	+92.6%	+74.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financial Basis	Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 · Market data at 2026-11-01 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 · Market data at 2026-11-01 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14	Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-04-29 Score computed: 2026-11-14

Where It Passes

Valuation models100% pass✓ 6▾
MRM undervalued: all 6 models price fair value above $0.28 (median $3.11)
Graham fair value$1.75
✓Graham+84.2% margin vs $0.28
Buffett fair value$3.50
✓Buffett+92.1% margin vs $0.28
Lynch fair value$4.54
✓Lynch+93.9% margin vs $0.28
Dreman fair value$2.72
✓Dreman+89.8% margin vs $0.28
Pabrai fair value$3.75
✓Pabrai+92.6% margin vs $0.28
Akre fair value$1.07
✓Akre+74.1% margin vs $0.28
Valuation54% pass✓ 19✗ 9▾
7 of 13 pass — Greenblatt, Dreman, Ackman +3 more object
Price / 3-yr avg EPS1.5x
✓Graham<= 15x
Price-to-Book Ratio0.4x
✓Graham<= 1.5x
P/E x P/B0.60
✓Graham<= 22.5
Basic earnings-growth PEG (dividends excluded)0.04
✓Lynch< 1.0 (ideally < 0.5)
EBIT / Enterprise Value-1.3%
✗Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=-1.3%, ROC=N/A (invested capital <= 0)
✗GreenblattBoth EY > 10% and ROC > 25%
Price / EPS1.5x
✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
Price / (CFO / Shares)N/A (negative CFPS)
✗Dreman< 8x
Price / Book Value per Share0.4x
✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
Valuation ReasonablenessP/E=1.5x, OE Yield=106.9%
✓MungerP/E < 25 or Owner Earnings Yield > 5%
P/E or FCF YieldP/E=1.5x, FCF Yield=-408.3%
✓PabraiP/E < 15 or FCF Yield > 10%
P/B or P/E vs. Historical AverageP/E=1.5x, P/B=0.4x
✓MarksP/E < 15 or P/B < 2.0
Discount to Intrinsic Value89.8% (IV=$2.72 vs Price=$0.28)
✓Marks>= 20% below intrinsic value
Price / FCF per ShareN/A (negative FCF)
✗Ackman<= 25
Price vs. Trailing Low100% of trailing low ($0.28)
✓Templeton<= 120% of trailing low (certified split-adjusted live window)
Net income / market capitalization+43.29%; #156/6340 (top 2.5%)
✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
Positive book equity / market capitalization+2.7159; #503/6449 (top 7.8%)
✓AsnessTop 30% of eligible cross-section
Price / Diluted EPS1.5x
✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
(EPS CAGR % + Dividend Yield %) / P/E
✗Neff> 0.7 (Neff's published traditional edge)
Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
✗SchlossP/TBV <= 1.00x (app cutoff)
Book Value per Share Change
✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
Revenue / market capitalization+24.1509; #186/5247 (top 3.5%)
✓OshaughnessyTop 10% of eligible cross-section
(Operating cash flow - capex) / market capitalization-408.31%; #4320/4519 (top 95.6%)
✗OshaughnessyTop 10% of eligible cross-section
Trailing six-month price return through the evaluation date-75.05%; #5752/6202 (top 92.7%)
✗OshaughnessyTop 10% of eligible cross-section

Where It Falls Short

Debt & Leverage8% pass✓ 1✗ 14▾
11 of 12 flag MRM's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current AssetsLT Debt $4.9M vs NCA $-9.4M
✗GrahamLT Debt <= Net Current Assets
Debt/Equity & Interest CoverageD/E: 1.48, IC: -0.4x
✗BuffettD/E < 0.5 AND Interest Coverage > 5x
Total Debt / Equity1.48
✗Lynch< 0.33
Cash - Long-term Debt$-2.8M
✗LynchPositive preferred
LT Debt / Total Assets Change15.34% -> 9.45%
✓PiotroskiDecreased YoY
Current Assets / Current Liabilities0.65
✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
Total Debt / Shareholders' Equity1.48
✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
Debt Levels1.48
✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
Interest Coverage & Debt/EBITDAIC=-0.4x, D/EBITDA=5.1x
✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
Total Debt / Shareholders Equity1.48
✗Ackman<= 1.0
Negative debt-to-equity (higher means less debt)-1.4840; #3581/4210 (top 85.1%)
✗AsnessTop 30% of eligible cross-section
Efficiency13% pass✓ 2✗ 9▾
7 of 8 flag MRM's efficiency — Graham, Buffett, Greenblatt +4 more
Current Ratio0.65
✗Graham>= 2.0
ROIC (3-5 yr avg)-24.1%
✗Buffett> 10%
ROIC - WACC-34.1%
✗BuffettPositive (WACC = 10%)
EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
✗Greenblatt> 25%
Current Ratio Change YoY0.49 -> 0.65
✓PiotroskiIncreased YoY
Revenue / Total Assets Change YoY1.00x -> 1.03x
✓PiotroskiImproved YoY
Current Assets / Current Liabilities0.65
✗Dreman> 1.5
Return on Invested Capital-0.6%
✗Munger> 15%
ROIC (high and growing)FY2022: ROIC=6.4%; FY2023: ROIC=-22.7%; FY2024: ROIC=-0.6%
✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
Reinvestment Rate x ROIC-0.6% (RR=100% x ROIC=-0.6%)
✗AkreReinvestment Rate * ROIC > 10%
ROIC (5-year)0/5 years above 12% (latest -0.6%)
✗SleepROIC > 12% in a majority of years
Verdicts17% pass✓ 2✗ 10▾
Split decision: 10 FAIL · 4 NEUTRAL · 2 PASS
Overall verdict
✗GrahamFAIL (3/9)✗BuffettFAIL (2/9)✗LynchFAIL (4/7)•GreenblattNot ranked•PiotroskiNEUTRAL (F-Score 6)✓DremanPASS (5/11)✓MungerPASS (2/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)✗AckmanFAIL (3/9)•TempletonNEUTRAL (5/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1452/2370 (Top 61.3%))✗NeffFAIL (2/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
Profitability19% pass✓ 16✗ 19▾
13 of 16 flag MRM's profitability — Graham, Buffett, Greenblatt +10 more
Positive EPS (10 years)4/7 years positive
✗GrahamPositive EPS every year for 10 years
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
✗Graham>= 33% growth
Net Income Positive (10+ years)4/7 years positive
✗BuffettPositive every year for 10+ years
ROE (up to 5-year arithmetic mean)-9.0%
✗Buffett> 15% arithmetic mean (app rule)
Operating Margin (10-yr trend)-0.2% (latest)
✓BuffettStable or rising over 10 years
Free Cash Flow Proxy$2.3M
✓BuffettPositive and growing
Earnings Variance (10-yr CoV)N/A (negative mean EPS)
✗BuffettCoV < 0.3
Retained Earnings Effectiveness
✗Buffett$1 retained -> > $1 market value created
Basic earnings-growth PEG (dividends excluded)0.04
✓Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR37.3%
✓Lynch15-30% (Fast Grower); > 0% to pass
ROE15.9%
✓Lynch> 15%
EBIT / Enterprise Value-1.3%
✗Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=-1.3%, ROC=N/A (invested capital <= 0)
✗GreenblattBoth EY > 10% and ROC > 25%
Net Income / Total Assets1.84%
✓PiotroskiROA > 0
ROA Change YoY1.68% -> 1.84% (delta: +0.15%)
✓PiotroskiCurrent ROA > Prior ROA
(CFO / Total Assets) vs ROACFO/Assets=-16.46%, ROA=1.84%
✗PiotroskiCFO/Assets > ROA
Gross Margin Change YoY23.0% -> 27.1%
✓PiotroskiImproved YoY
Pre-Tax Income / Revenue0.6%
✗Dreman>= 8%
Net Income / Shareholders' Equity15.9%
✓Dreman> 12%
Margin of SafetyP/E=1.5x, P/B=0.4x
✓PabraiP/B < 1.5 or P/E < 15
Return on Equity-13.0% (3-yr avg)
✗AkreROE > 20% (3-year avg)
Discount to Intrinsic Value89.8% (IV=$2.72 vs Price=$0.28)
✓Marks>= 20% below intrinsic value
Positive Net Income Frequency4/6 years positive
✗MarksPositive net income in >= 7 of last 10 years
Operating Income / Revenue-0.2%
✗Ackman>= 15%
Net Income / Shareholders Equity15.9%
✓Ackman>= 15%
5-Year EPS CAGR37.3% CAGR over 5 years
✓Templeton> 0% (5-year EPS CAGR)
Operating Margin Trend1.4% (2022) -> -0.2% (2024)
✗TempletonNon-negative operating-margin trend over 3 years
Revenue growth vs. gross and operating margin trendgross margin 27.4% -> 27.1%, operating margin 1.4% -> -0.2%
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
Net income / market capitalization+43.29%; #156/6340 (top 2.5%)
✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
Gross profit / total assets+27.76%; #1557/3702 (top 42.1%)
✗AsnessTop 30% of eligible cross-section
Net income / positive book equity+15.94%; #1079/5226 (top 20.6%)
✓AsnessTop 30% of eligible cross-section
Negative 5-year standard deviation of ROA-0.0786; #3176/5884 (top 54.0%)
✗AsnessTop 30% of eligible cross-section
3-5 Year Diluted EPS CAGR37.3% over 5 years
✗Neff7%-20% annualized
Positive Diluted-EPS Years4/6 years positive
✗Schloss>= 70% positive over 5-10 observed years (app rule)
Cash Flow20% pass✓ 2✗ 10▾
8 of 10 flag MRM's cash flow — Lynch, Piotroski, Dreman +5 more
Free Cash Flow Proxy$2.3M
✓BuffettPositive and growing
FCF Positive and Growing$-8.9M
✗LynchPositive and growing
Operating Cash Flow$-8.5M
✗PiotroskiCFO > 0
(CFO / Total Assets) vs ROACFO/Assets=-16.46%, ROA=1.84%
✗PiotroskiCFO/Assets > ROA
Price / (CFO / Shares)N/A (negative CFPS)
✗Dreman< 8x
P/E or FCF YieldP/E=1.5x, FCF Yield=-408.3%
✓PabraiP/E < 15 or FCF Yield > 10%
FCF Positive1/6 years FCF positive
✗MarksPositive FCF in majority of recent years
(OCF - CapEx) / Market Cap-408.3%
✗Ackman>= 4%
Price / FCF per ShareN/A (negative FCF)
✗Ackman<= 25
Positive Operating Cash Flow frequency1/6 years positive
✗SleepPositive OCF in >= 70% of available years
Operating Cash Flow - Capital Expenditures$-8.9M
✗Neff> $0 (app proxy for a strong fundamental case)
(Operating cash flow - capex) / market capitalization-408.31%; #4320/4519 (top 95.6%)
✗OshaughnessyTop 10% of eligible cross-section
Growth38% pass✓ 8✗ 5▾
5 of 8 flag MRM's growth — Graham, Marks, Ackman +2 more
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
✗Graham>= 33% growth
Basic earnings-growth PEG (dividends excluded)0.04
✓Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR37.3%
✓Lynch15-30% (Fast Grower); > 0% to pass
Inventory Growth vs Revenue GrowthInv: -2.4% vs Rev: 9.5%
✓LynchInventory growth < Revenue growth
EPS Growth Direction$0.04 (2019) -> $0.18 (2024)
✓DremanPositive over recent years
EPS CAGR37.3% CAGR over 5 years
✓Dreman> 5% annualized
Positive Net Income Frequency4/6 years positive
✗MarksPositive net income in >= 7 of last 10 years
3yr Median Revenue Growth9.5%
✓Ackman>= 5%
Positive EPS Growth Frequency2/5 years with positive EPS growth
✗AckmanPositive EPS growth in >= 3 of last 5 years
5-Year EPS CAGR37.3% CAGR over 5 years
✓Templeton> 0% (5-year EPS CAGR)
Revenue growth vs. gross and operating margin trendgross margin 27.4% -> 27.1%, operating margin 1.4% -> -0.2%
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
5-year Revenue CAGR8.0%
✓SleepCAGR > 7%
3-5 Year Diluted EPS CAGR37.3% over 5 years
✗Neff7%-20% annualized

Business & financials

Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

Company Profile

Industry: Personal Services

Size: Micro Cap($2.2M)

Revenue: $52.9M+9.5% YoY

Net Income: $947565.25+16.1% YoY

Financial Snapshot

Operating Margin-0.2%

Return on Equity15.9%

Debt / Equity1.48

Current Ratio0.65

EPS (Diluted)$0.18+15.0% 1y

Similar Companies

EDUNew Oriental Education & Technology Group Inc.

$8.3B

HRBH&R BLOCK INC

$6.1B

TALTAL Education Group

$5.7B

GHCGraham Holdings Co

$5.2B

Shareholder Return

Fiscal 2024

Share retirement not available for this company.

Buybacks: —
Dividends: —

What drove EPS

A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

FY23

−22.9% = −27.2% + 5.9%

FY24

15.0% = 16.1% + −1.0%

Earnings Fewer shares More shares

The two parts do not sum exactly to the total — the difference is the cross-term, plus preferred capital where the company has any. It is left visible rather than distributed into the other two.

Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

Metric	FY 2024 Sources 20-F · 2025-04-29	FY 2023 Sources 20-F · 2024-06-18	FY 2022 Sources 20-F · 2023-05-30	FY 2021 Sources 20-F · 2022-11-14	FY 2020 Sources 20-F · 2021-05-17
Market Cap	$2.2Mcurrent	$29.3Mest.	$30.6Mest.	$31.9Mest.	$69.3Mest.
Revenue	$52.9M↑9%	$48.3M↓8%	$52.3M↑11%	$47.0M↑45%	$32.4M
Operating Income	-$115.3K↑96%	-$2.8M↓480%	$729.5K↑118%	-$4.1M↑43%	-$7.2M
Net Income	$947.6K↑16%	$816.0K↓27%	$1.1M↑113%	-$8.6M↓65%	-$5.2M
EPS (Diluted)	$0.18↑15%	$0.16↓23%	$0.20↑112%	$-1.77↓36%	$-1.30
Gross Margin	27.1%↑18%	23.0%↓16%	27.4%	—	—
Operating Margin	-0.2%↑96%	-5.7%↓511%	1.4%↑116%	-8.7%↑61%	-22.3%
ROE	15.9%↓71%	54.7%↑122%	-250.9%↓153%	475.5%↑533%	-109.8%
Total Debt	$8.8M↑8%	$8.1M↓13%	$9.4M↑19%	$7.9M↓11%	$8.8M
Shareholders' Equity	$5.9M↑299%	$1.5M↑434%	-$446.7K↑75%	-$1.8M↓138%	$4.8M
Current Ratio	0.65↑31%	0.49↓24%	0.65↑50%	0.43↓45%	0.79
Debt / Equity	1.48↓73%	5.46↑126%	-21.03↓382%	-4.36↓335%	1.85
Operating Cash Flow	-$8.5M↓90%	-$4.5M↑13%	-$5.2M↓7%	-$4.8M↓36%	-$3.6M
Free Cash Flow	-$8.9M↓65%	-$5.4M↑11%	-$6.1M↓7%	-$5.7M↓33%	-$4.3M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Personal Services

MRM vs Peers — Financial Grading

Revenue$52.9MBottom 25%

Net Income$947565.25Bottom 25%

ROE15.9%Median

D/E1.48Bottom 25%

Op. Margin-0.2%Bottom 25%

Curr. Ratio0.65Bottom 25%

Company	Market Cap	Price	Revenue	Net Income	ROE	D/E	Op. Margin	Curr. Ratio	Graham	Buffett	Lynch	Greenblatt	Piotroski	Dreman
New Oriental Education & Technology Group Inc.EDU	$8.3B	$53.28	$4.9B	$371.7M	10.2%	0.00	8.7%	1.58	1/9	2/9	3/7	1/3	F-Score 7	6/11
H&R BLOCK INCHRB	$6.1B	$50.01	$3.8B	$605.8M	681.4%	20.73	22.0%	0.90	3/9	4/9	3/7	1/3	F-Score 4	4/11
TAL Education GroupTAL	$5.7B	$10.28	$3.0B	$530.8M	14.1%	—	9.2%	2.17	6/9	2/9	3/7	1/3	F-Score 8	9/11
Graham Holdings CoGHC	$5.2B	$1244.05	$4.9B	$292.3M	6.1%	0.18	4.8%	1.75	6/9	0/9	3/7	0/3	F-Score 6	5/11
LAUREATE EDUCATION, INC.LAUR	$4.8B	$35.03	$1.7B	$281.6M	23.7%	0.11	25.3%	0.67	1/9	5/9	6/7	3/3	F-Score 6	4/11
UNIFIRST CORPUNF	$4.3B	$235.39	$2.4B	$148.3M	6.8%	—	7.6%	3.18	3/9	5/9	2/7	0/3	F-Score 6	3/11
Covista Inc.CVSA	$3.9B	$118.17	$2.0B	$251.6M	17.4%	0.46	19.6%	1.09	1/9	4/9	5/7	0/3	F-Score 6	4/11
BRIGHT HORIZONS FAMILY SOLUTIONS INC.BFAM	$2.5B	$52.68	$2.9B	$193.1M	14.4%	0.56	10.7%	0.52	1/9	1/9	4/7	0/3	F-Score 8	3/11